Genomic Instability in EBV-Transformed Lymphoblastoid Cell Lines

Total Page:16

File Type:pdf, Size:1020Kb

Genomic Instability in EBV-Transformed Lymphoblastoid Cell Lines Genomic instability in EBV-transformed lymphoblastoid cell lines Ji Hee Oh The Graduate school Yonsei University Graduate Program in Science for Aging Genomic instability in EBV-transformed lymphoblastoid cell lines Dissertation Submmitted to Graduate Program in Science for Aging And Graduated school Yonsei University In partial fulfillment of the requirements For the degree of Doctor of Philosophy Ji Hee Oh December 2013 감사의 글 길고도 짧았던 박사 학위 과정을 미흡하나마 논문으로 결실을 맺게 되었습 니다. 그 동안 많은 가르침과 격려 해주신 모든 분들께 이 글을 통하여 감사의 마음을 전합니다. 무엇보다도 부족한 저에게 배움의 기회를 주시고 많은 가르침을 주신 이종 호 교수님께 고개 숙여 깊이 감사 드립니다. 바쁘신 가운데 변함없이 관심 을 가져주신 이수복 교수님, 이승민 교수님께 감사의 인사를 드립니다. 석 사 학위과정 때부터 꾸준히 학문적으로 많은 가르침을 주신 채지숙 교수님, 김오연 교수님, 정지형 교수님께 감사의 인사를 드립니다. 대학원 전 과정 동안 가장 오랜시간동안 도와주고 걱정해 준 진태원군 너 무 고마웠습니다. 박사 학위과정 입학과 졸업을 같이 할 수 있어서 너무 기쁘며 축하합니다. 김윤경 선생님, 박사되고 승급하고 결혼도하고 너무 축하해요. 같이 졸업 준비하면서 고생도 많이 하고 고맙고 고생 많았습니 다. 오랜 시간 동안 학위과정을 할 수 있도록 도와주신 형질연구 과 선생님들 에게 고마운 마음을 전합니다. 김봉조 과장님, 김흥태 연구사님, 이주영 연 구사님 감사합니다. 너무 많은 도움을 항상 받으면서 논문 준비도 같이 해 준 김영진 선생님 진심으로 고맙습니다. 불광동에서부터 지금까지 변치 않 고 항상 많은 도움을 주신 문상훈 박사님 감사합니다. 두 분의 도움으로 논문을 완성할 수 있었습니다. 지금은 떨어져있어 그리운 김남희 선생님, 이은주 박사님, 박미의 박사님, 김동준 선생님, 김광중 박사님, 복정 선생 님의 진심 어린 충고 감사하고 보고 싶습니다. 많은 시간을 같이 보내진 않았지만 항상 옆에 있어준 김연정 선생님, 황미영 선생님, 윤준호 선생님, 허룡 선생님 앞으로도 더욱 많이 서로 도와주고 서로 힘이 되어주는 사이 가 계속 되었으면 좋겠습니다. 국립보건연구원 형질연구과의 황주연 선생 님, 고민진 선생님, 김정민 선생님, 이헌식 선생님, 배재범 선생님, 박수연 선생님, 이영 선생님, 박인규 선생님, 박태준 선생님, 유호영 선생님, 송영 웅 선생님, 최지영 선생님, 한소희 선생님 항상 도와주셔서 감사합니다. 이세상 누구보다 사랑하는 나의 가족에게 고마움과 감사함을 전합니다. 언 제나 부모님의 기대에 미치지는 못하지만 사랑과 믿음으로 묵묵하게 저의 뒷바라지를 해주셨기에 오늘의 제가 있을 수 있었습니다. 크나큰 은혜에 이 결실 조금이나마 부모님께 기쁨을 드리고 싶습니다. 지금은 홀로 해외 에 있는 하나밖에 없는 내 동생, 항상 걱정하고 고맙고 사랑 하다고 전하 고 싶습니다. 항상 내 의견을 존중해주고 양보해주고 언제나 큰 힘이 되 어준 지민기군에게 사랑하고 고마운 마음을 전하고 싶습니다. 저의 이 모든 결실인 부모님께 이 논문을 바칩니다. 2014년 1월 오지희 드림 CONTENTS List of Figures ································································· v List of Tables ····························································· vi List of Appendices ···················································· viii ABSTRACT ······························································· ix Ⅰ. BACKGROUND ······················································· 1 1. LYMPHOBLSTOID CELL LINES (LCLs) ····························· 1 1.1. Epstein-Barr Virus (EBV) ············································ 1 1.2. EBV immortalization ················································· 2 1.3. Subculture ······························································· 3 2. GENOMIC ABERRATION ··············································· 3 2.1. Copy number variation (CNV) ···································· 3 2.2. Loss of heterozygosity (LOH) ····································· 4 2.3. Silent LOH ······························································ 4 3. MICROARRAY TECHNOLOGY ······································· 5 i Ⅱ. GENOTYPE INSTABILITY DURING LONG- TERM SUBCULTURE OF LYMPHOBLASTOID CELL LINES ·································································· 6 1. INTRODUCTION ························································· 6 2. SUBJECTS AND METHODS ··········································· 8 2.1. Samples ································································· 8 2.2. Subculture of LCLs ··················································· 9 2.3. Genotyping ··························································· 12 2.4. Examination of genotype concordance ······················· 12 3. RESULTS ··································································· 13 3.1. Estimated genotype instability in LCLs and PBMCs across sample pairs ·················································· 13 3.1.1. Investigation of concordance of SNP genotypes between LCLs and PBMCs ································· 13 3.1.2. Test of the concordance of GWAS SNPs ·············· 17 3.1.3. Calculation of genotype concordance between LCLs and PBMCs ··········································· 19 3.1.4. Identification of the chromosomal regions vulnerable to genotyping errors ························ 22 ii 3.1.5. Detection of loss of heterozygosity regions ············ 30 4. DISCUSSION ······························································· 36 Ⅲ. INTEGRATED GENOMIC ABERRATION, GENE EXPRESSION AND miRNA EXPRESSION ANALYSIS IN LYMPHOBLASTOID CELL LINE DURING LONG- TERM CELL CULTURE ·········································· 39 1. INTRODUCTION ······················································· 39 2. MATERIALS AND METHODS ······························· 41 2.1. Samples ····································································· 41 2.2. Genotyping ································································· 43 2.3. Gene expression microarray ············································ 43 2.4. miRNA microarray ······················································· 44 2.5. Gene ontology analysis ·················································· 44 3. RESULTS ··································································· 45 3.1. Exome array genotyping ··········································· 45 3.2. CNV and LOH detection ··········································· 45 3.3. Identification of differentially expressed genes ·············· 48 3.4. Functional correlation of DEGs ·································· 51 3.5. Identification of DEGs overlapped with CNVs ·············· 58 iii 3.6. Functional correlation of DEGs overlapped with CNVs··· 61 4. DISCUSSION ······························································· 66 REFERENCES ···························································· 69 ABSTRACT IN KOREAN ·············································· 75 APPENDICES ···························································· 77 iv List of Figures Figure 1. Boxplot: Genotype concordance of between PBMC and LCLs at 6 different propagation stages ·························· 18 Figure 2. Comparison of genotype concordance of LCLs among SNP based on the chromosomal location. ······················ 23 Figure 3. The LOH observed in chromosome ······························ 25 Figure 4. The LOH identified at different chromosomal regions ···· 31 v List of Tables Table 1. Description of samples ··············································· 11 Table 2. Genotype concordance between PBMCs and LCLs from SNP filtered call rate ················································· 15 Table 3. Estimation of the concordance rate between duplicated6 experiments from the same samples ······························ 16 Table 4. Comparison of genotype concordance of LCLs among SNP groupings based on missing rate, HWE p-value, and MAF ······················································ 21 Table 5. LOH with increased numbers of LCL passages through culture ····································································· 24 Table 6. Description of samples ··············································· 42 Table 7. Detecting LOH regions ··············································· 47 Table 8. Integration of gene expression data in ≥5 samples with 10 top signals ordered by M-value ································· 49 Table 9. Integration of miRNA expression data in ≥5 samples with 10top signals ordered by M-value··························· 50 vi Table 10. Functional annotation clusters of significant DEGs from gene expression data with top clusters ordered by FDR ··································································· 52 Table 11. Functional annotation clusters of significant DEGs from miRNA expression data with top clusters ordered by FDR ··································································· 55 Table 12. Integration of CNVs with gene expression data ·············· 59 Table 13. Integration of CNVs with miRNA expression data·········· 60 Table 14. Functional annotation clusters of significant DEGs with CNVs from gene expression data ·························· 62 Table 15. Functional annotation clusters of significant DEGs with CNVs from miRNA expression data ······················ 63 vii List of Appendices Appendix Ⅰ. Detection of CNVs by exome chip ························· 78 Appendix Ⅱ. Functional annotation clusters of significant DEGs from gene expression data ···································· 89 Appendix Ⅲ. Functional annotation clusters of significant differentially expression genes from miRNA expression data ················································· 92 Appendix Ⅳ. Functional annotation clusters of significant DEGs with CNVs from miRNA expression data ··············· 105 viii ABSTRACT Genotype instability in EBV-transformed lymphoblastoid cell lines Ji Hee Oh Graduate Program Science for Aging The Graduate School Yonsei University Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) promise to address the challenge posed by the limited availability of primary cells needed as a source of genomic DNA for genetic studies. However, the genetic stability of LCLs following prolonged culture has never been rigorously investigated. The impact of genomic aberration on the biological experiments such as gene ix expression and miRNA expression level has not been explored. Purposes of current study are to investigate whether genetic instability of LCLs might cause the accumulation of genetic modifications following their long-term subculture and to examine a correlation between genomic aberration and expression level in genes and miRNAs. To accomplish our goals, we isolated genomic DNA from human peripheral blood mononuclear cells and LCLs collected from 20 individuals and genotyped
Recommended publications
  • SEC23IP (NM 007190) Human Recombinant Protein – TP309056
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP309056 SEC23IP (NM_007190) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human SEC23 interacting protein (SEC23IP) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 110.9 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_009121 Locus ID: 11196 UniProt ID: Q9Y6Y8 RefSeq Size: 7306 Cytogenetics: 10q26.11-q26.12 RefSeq ORF: 3000 Synonyms: iPLA1beta; MSTP053; P125; P125A Summary: This gene encodes a member of the phosphatidic acid preferring-phospholipase A1 family. The encoded protein is localized to endoplasmic reticulum exit sites and plays a critical role in ER-Golgi transport as part of the multimeric coat protein II complex. An orthologous gene in frogs is required for normal neural crest cell development, suggesting that this gene may play a role in Waardenburg syndrome neural crest defects. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Feb 2011] This product is to be used for laboratory only.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Genetic Variant in 3' Untranslated Region of the Mouse Pycard Gene
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 2 3 Title: 4 Genetic Variant in 3’ Untranslated Region of the Mouse Pycard Gene Regulates Inflammasome 5 Activity 6 Running Title: 7 3’UTR SNP in Pycard regulates inflammasome activity 8 Authors: 9 Brian Ritchey1*, Qimin Hai1*, Juying Han1, John Barnard2, Jonathan D. Smith1,3 10 1Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, 11 Cleveland, OH 44195 12 2Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 13 44195 14 3Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western 15 Reserve University, Cleveland, OH 44195 16 *, These authors contributed equally to this study. 17 Address correspondence to Jonathan D. Smith: email [email protected]; ORCID ID 0000-0002-0415-386X; 18 mailing address: Cleveland Clinic, Box NC-10, 9500 Euclid Avenue, Cleveland, OH 44195, USA. 19 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 20 Abstract 21 Quantitative trait locus mapping for interleukin-1 release after inflammasome priming and activation 22 was performed on bone marrow-derived macrophages (BMDM) from an AKRxDBA/2 strain intercross.
    [Show full text]
  • The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis
    cancers Article The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis Jacek Marzec 1,† , Helen Ross-Adams 1,*,† , Stefano Pirrò 1 , Jun Wang 1 , Yanan Zhu 2, Xueying Mao 2, Emanuela Gadaleta 1 , Amar S. Ahmad 3, Bernard V. North 3, Solène-Florence Kammerer-Jacquet 2, Elzbieta Stankiewicz 2, Sakunthala C. Kudahetti 2, Luis Beltran 4, Guoping Ren 5, Daniel M. Berney 2,4, Yong-Jie Lu 2 and Claude Chelala 1,6,* 1 Bioinformatics Unit, Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (J.M.); [email protected] (S.P.); [email protected] (J.W.); [email protected] (E.G.) 2 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (Y.Z.); [email protected] (X.M.); solenefl[email protected] (S.-F.K.-J.); [email protected] (E.S.); [email protected] (S.C.K.); [email protected] (D.M.B.); [email protected] (Y.-J.L.) 3 Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (A.S.A.); [email protected] (B.V.N.) 4 Department of Pathology, Barts Health NHS, London E1 F1R, UK; [email protected] 5 Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou 310058, China; [email protected] 6 Centre for Computational Biology, Life Sciences Initiative, Queen Mary University London, London EC1M 6BQ, UK * Correspondence: [email protected] (H.R.-A.); [email protected] (C.C.) † These authors contributed equally to this work.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • SEC23IP (NM 007190) Human Tagged ORF Clone – RG209056
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RG209056 SEC23IP (NM_007190) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: SEC23IP (NM_007190) Human Tagged ORF Clone Tag: TurboGFP Symbol: SEC23IP Synonyms: iPLA1beta; MSTP053; P125; P125A Vector: pCMV6-AC-GFP (PS100010) E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 SEC23IP (NM_007190) Human Tagged ORF Clone – RG209056 ORF Nucleotide >RG209056 representing NM_007190 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGCCGAGAGAAAACCTAACGGTGGCAGCGGCGGCGCCTCCACTTCCTCATCGGGCACTAACTTACTTT TCTCCTCCTCGGCCACGGAGTTCAGCTTCAATGTGCCCTTCATCCCAGTCACCCAGGCCTCCGCTTCTCC GGCCTCCCTGCTCTTACCGGGAGAGGATTCCACAGATGTTGGTGAGGAGGACAGCTTCCTTGGTCAGACT TCTATTCACACATCTGCCCCACAGACATTTAGTTACTTCTCTCAGGTATCAAGCAGCAGTGATCCTTTTG GGAATATTGGACAGTCACCATTAACAACTGCAGCAACCTCAGTTGGACAATCAGGATTCCCCAAGCCCCT GACTGCTCTCCCTTTTACAACTGGATCCCAAGATGTCTCGAATGCATTTTCACCATCCATTTCGAAGGCT CAACCTGGTGCTCCACCTTCCTCACTGATGGGAATAAATTCTTATCTGCCTTCTCAGCCAAGTAGTCTCC CTCCTTCATATTTTGGGAACCAACCCCAAGGAATTCCCCAACCAGGATACAATCCATATCGCCATACCCC TGGCAGCAGCAGGGCTAATCCTTACATTGCACCACCCCAGCTGCAGCAGTGCCAAACACCAGGCCCTCCT
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • SCAP/SREBP Pathway Is Required for the Full Steroidogenic Response To
    SCAP/SREBP pathway is required for the full PNAS PLUS steroidogenic response to cyclic AMP Masami Shimizu-Alberginea,b,c, Brian Van Yserloob,c, Martin G. Golkowskia, Shao-En Onga, Joseph A. Beavoa,1,2, and Karin E. Bornfeldtb,c,d,1,2 aSchool of Medicine, Department of Pharmacology, University of Washington, Seattle, WA 98195; bSchool of Medicine, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA 98109; cUniversity of Washington Diabetes Institute, School of Medicine, University of Washington, Seattle, WA 98109; and dSchool of Medicine, Department of Pathology, University of Washington Diabetes Institute, University of Washington, Seattle, WA 98109 Contributed by Joseph A. Beavo, July 19, 2016 (sent for review May 14, 2016; reviewed by Marco Conti, Donald Maurice, and Timothy Osborne) Luteinizing hormone (LH) stimulates steroidogenesis largely through Cellular cholesterol levels are controlled in part by several a surge in cyclic AMP (cAMP). Steroidogenic rates are also critically transcription factors, including sterol-regulatory element-binding dependent on the availability of cholesterol at mitochondrial sites of proteins (SREBPs) 2 and 1a, that promote cholesterol bio- synthesis. This cholesterol is provided by cellular uptake of lipoproteins, synthetic gene expression when cellular cholesterol levels are too mobilization of intracellular lipid, and de novo synthesis. Whether low to meet demand (9, 10). The activities of the SREBPs are and how these pathways are coordinated by cAMP are poorly un- precisely controlled by an escort protein, SREBP cleavage-acti- derstood. Recent phosphoproteomic analyses of cAMP-dependent vating protein (SCAP), and the insulin-inducible gene product phosphorylation sites in MA10 Leydig cells suggested that cAMP (Insig) (11–13).
    [Show full text]
  • ID AKI Vs Control Fold Change P Value Symbol Entrez Gene Name *In
    ID AKI vs control P value Symbol Entrez Gene Name *In case of multiple probesets per gene, one with the highest fold change was selected. Fold Change 208083_s_at 7.88 0.000932 ITGB6 integrin, beta 6 202376_at 6.12 0.000518 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 1553575_at 5.62 0.0033 MT-ND6 NADH dehydrogenase, subunit 6 (complex I) 212768_s_at 5.50 0.000896 OLFM4 olfactomedin 4 206157_at 5.26 0.00177 PTX3 pentraxin 3, long 212531_at 4.26 0.00405 LCN2 lipocalin 2 215646_s_at 4.13 0.00408 VCAN versican 202018_s_at 4.12 0.0318 LTF lactotransferrin 203021_at 4.05 0.0129 SLPI secretory leukocyte peptidase inhibitor 222486_s_at 4.03 0.000329 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1552439_s_at 3.82 0.000714 MEGF11 multiple EGF-like-domains 11 210602_s_at 3.74 0.000408 CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 229947_at 3.62 0.00843 PI15 peptidase inhibitor 15 204006_s_at 3.39 0.00241 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 202238_s_at 3.29 0.00492 NNMT nicotinamide N-methyltransferase 202917_s_at 3.20 0.00369 S100A8 S100 calcium binding protein A8 215223_s_at 3.17 0.000516 SOD2 superoxide dismutase 2, mitochondrial 204627_s_at 3.04 0.00619 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 223217_s_at 2.99 0.00397 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 231067_s_at 2.97 0.00681 AKAP12 A kinase (PRKA) anchor protein 12 224917_at 2.94 0.00256 VMP1/ mir-21likely ortholog
    [Show full text]
  • UNIVERSITY of CALIFORNIA Los Angeles a Sterile Alpha Motif
    UNIVERSITY OF CALIFORNIA Los Angeles A Sterile Alpha Motif Domain Network Involved in Kidney Development A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Biochemistry and Molecular Biology by Catherine Nicole Leettola 2015 ABSTRACT OF THE DISSERTATION A Sterile Alpha Motif Domain Network Involved in Kidney Development by Catherine Nicole Leettola Doctor of Philosophy in Biochemistry and Molecular Biology University of California, Los Angeles, 2015 Professor James U. Bowie, Chair Cystic kidney diseases including polycystic kidney disease (PKD) and nephronophthisis (NPHP) are the most common genetic disorders leading to end-stage renal failure in humans. Animal models and human cases of PKD and NPHP have implicated the sterile alpha motif (SAM) domain containing proteins bicaudal C homolog 1 (BICC1) and ankyrin repeat and SAM- domain containing protein 6 (ANKS6) as being involved in these conditions and important for renal development. SAM domains are known protein-protein interaction domains that are capable of binding each other to form polymers and heterodimers. Using a negGFP native gel assay, we have identified the SAM domain of the previously uncharacterized protein ankyrin repeat and SAM-domain containing protein 3 (ANKS3) as a direct binding partner of the BICC1 and ANKS6 SAM domains. We found the ANKS3 SAM domain to polymerize with moderate affinity and determined the ANKS6 SAM domain can bind to a single end of this polymer. Crystal structures of the ANKS3 SAM domain polymer and the ANKS3 SAM-ANKS6 SAM ii heterodimer are presented to reveal typical ML-EH SAM domain interaction interfaces with a pronounced charge complementarity.
    [Show full text]
  • Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families with Neurodevelopmental Disorders
    Research JAMA Psychiatry | Original Investigation Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders Miriam S. Reuter, MD; Hasan Tawamie, MA; Rebecca Buchert, MA; Ola Hosny Gebril, MD; Tawfiq Froukh, PhD; Christian Thiel, MD; Steffen Uebe, PhD; Arif B. Ekici, PhD; Mandy Krumbiegel, PhD; Christiane Zweier, MD; Juliane Hoyer, MD; Karolin Eberlein, MD; Judith Bauer, MD; Ute Scheller, MD; Tim M. Strom, MD; Sabine Hoffjan, MD; Ehab R. Abdelraouf, MD; Nagwa A. Meguid, MD, PhD; Ahmad Abboud, MD; Mohammed Ayman Al Khateeb, MD; Mahmoud Fakher, MD; Saber Hamdan, MD; Amina Ismael, MD; Safia Muhammad, MD; Ebtessam Abdallah, MD, PhD; Heinrich Sticht, PhD; Dagmar Wieczorek, MD; André Reis, MD; Rami Abou Jamra, MD Supplemental content IMPORTANCE Autosomal recessive inherited neurodevelopmental disorders are highly heterogeneous, and many, possibly most, of the disease genes are still unknown. OBJECTIVES To promote the identification of disease genes through confirmation of previously described genes and presentation of novel candidates and provide an overview of the diagnostic yield of exome sequencing in consanguineous families. DESIGN, SETTING, AND PARTICIPANTS Autozygosity mapping in families and exome sequencing of index patients were performed in 152 consanguineous families (the parents descended from a same ancestor) with at least 1 offspring with intellectual disability (ID). The study was conducted from July 1, 2008, to June 30, 2015, and data analysis was conducted from July 1, 2015, to August 31, 2016. RESULTS Of the 152 consanguineous families enrolled, 1 child (in 45 families [29.6%]) or multiple children (107 families [70.4%]) had ID; additional features were present in 140 of the families (92.1%).
    [Show full text]
  • Confidential: for Review Only Can the Impact of Childhood Adiposity on Disease Risk Be Reversed?: Mendelian Randomization Study
    BMJ Confidential: For Review Only Can the impact of childhood adiposity on disease risk be reversed?: Mendelian randomization study Journal: BMJ Manuscript ID BMJ-2019-052821 Article Type: Research BMJ Journal: BMJ Date Submitted by the 28-Sep-2019 Author: Complete List of Authors: Richardson, Tom; University of Bristol Faculty of Health Sciences, MRC Integrative Epidemiology Unit Sanderson, Eleanor; University of Bristol, Population Health Sciences Elsworth, Benjamin; University of Bristol, MRC Integrative Epidemiology Unit (IEU), Bristol Medical School: Population Health Science Tilling, Kate; University of Bristol Faculty of Health Sciences Davey Smith, George; MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine Keywords: Mendelian randomization, Mediation, Early life adiposity https://mc.manuscriptcentral.com/bmj Page 1 of 173 BMJ 1 2 3 4 Can the impact of childhood adiposity on disease risk be reversed? 5 6 A Mendelian randomization study 7 8 9 10 11 Tom G. Confidential:Richardson1,*, Eleanor Sanderson1 , ForBenjamin ReviewElsworth1, Kate Tilling Only1, George Davey Smith1 12 13 1MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of 14 15 Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom 16 17 18 19 *Corresponding author: Dr Tom G. Richardson, MRC Integrative Epidemiology Unit, Population 20 21 Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol 22 23 BS8 2BN, UK. Tel: +44 (0)117 3313370; E-mail: [email protected] 24 25 26 27 28 Word Count: 4,344 29 30 Key words: Mendelian randomization, Early life adiposity, Mediation 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 https://mc.manuscriptcentral.com/bmj BMJ Page 2 of 173 1 2 3 4 5 Abstract 6 Objective: To evaluate whether early life adiposity has an independent effect on later life 7 8 disease risk or whether its influence is mediated by adulthood body mass index (BMI).
    [Show full text]